Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ASCO Highlights In Brief

Executive Summary

Amgen's Prolia: Data presented at the American Society of Clinical Oncology meeting in Chicago included new information on the use of Amgen's RANK ligand inhibitor, Prolia (denosumab), in delaying skeletal related events in prostate cancer patients with bone metastases. The study met its primary and secondary endpoints showing superiority in a head-to-head trial against Novartis' Zometa (zoledronic acid) in postponing time to the first SRE by 20.7 months compared to 17.1 months. Overall, the data were inline with the expectations of analysts, who remain bullish on the compound in the wake of its approval in the post-menopausal osteoporosis setting and Amgen's decision to price the compound aggressively (1"The Pink Sheet," June 7, 2010). The study was typical of Amgen's showing at the June 4-7 cancer meeting, which was generally positive but incremental
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS052308

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel